NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.9600
+0.2100 (+12.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.7500
Open1.6200
Bid0.0000 x 1000
Ask0.0000 x 1200
Day's Range1.6200 - 2.0500
52 Week Range0.2300 - 4.0400
Volume3,326,847
Avg. Volume2,387,423
Market Cap37.225M
Beta (3Y Monthly)4.21
PE Ratio (TTM)N/A
EPS (TTM)-0.5710
Earnings DateMar 19, 2019 - Mar 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFO

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces the appointments of Justin Hall as President and Chief Executive Officer, and Jason Raleigh as Chief Financial Officer. Hall has served as interim President and CEO, and Raleigh as interim CFO since March 2019.

  • MarketWatch9 days ago

    NovaBay's stock halted for volatility 18 times as it rockets 557%

    NovaBay Pharmaceuticals Inc.'s stock has blasted off to a more-than 6-fold gain in extremely active Monday afternoon trading, after the specialty pharmaceutical company said its Avenova eye-care product is available to buy without a prescription on Amazon.com. The stock's rocket ride has been bumpy for investors, however, as it has been halted for volatility 18 times, between 10:21 a.m. Eastern and 1:37 p.m. The stock was up 557%, to pace all gainers trading on major market indexes. Trading volume topped 38.3 million shares, compared with the full-day average of about 1.2 million shares. NovaBay said Avenova Direct is available on Amazon in the U.S. in a 20 milliliter size for $29.99. The stock reached an intraday high of $3.02, or more than 9 times Friday's closing price of 32 cents, before paring some gains. It is currently on track to close at the highest level since Sept. 24, 2018. The stock has rallied 46% over the past three months, while the S&P 500 has gained 5.5%.

  • MarketWatch9 days ago

    NovaBay's stock more than triples after Avenova made available on Amazon without prescription

    Shares of NovaBay Pharmaceuticals Inc. more than tripled in very active premarket trade Monday, after the biopharmaceutical company said its Avenova eye-care product is now available without a prescription on Amazon.com through its new direct-to-consumer online channel. Avenova is a lid and lash spray, designed to remove bacteria and debris on and around the eyelid margin. The stock rocketed 262% on volume of 1.1 million shares, to make it the most actively traded ahead of the open. "While prescription Avenova continues to be available through retail pharmacies and direct in-office sales by certain eye care specialists, patients and physicians have asked for greater accessibility to the product," said NovaBay Chief Executive Justin Hall. "In response, we are launching our new U.S. direct-to-consumer channel, which is a significant step in ensuring easy access at an affordable price." The stock had tumbled 59% year to date through Friday, while the S&P 500 has gained 15%.

  • Business Wire9 days ago

    NovaBay Pharmaceuticals Launches Avenova® Direct on Amazon.com

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that Avenova® Direct is available at affordable pricing and without a prescription on Amazon.com through the Company’s new direct-to-consumer online channel. Avenova, the leading lid and lash spray, is designed for the removal of bacteria and debris on and around the eyelid margin that contribute to bacterial eye infections, which represent approximately 85% of the dry eye market.

  • Business Wire29 days ago

    NovaBay Pharmaceuticals Receives NYSE American Communication

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that on May 16, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide requiring stockholders’ equity of $2.0 million or more and $4.0 million or more, respectively, if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years. According to the Exchange, this notice does not impact the Company’s ongoing plan to regain compliance with continued listing standards, which requires the Company to regain such compliance by October 12, 2020 or be subject to delisting procedures.

  • Business Wirelast month

    NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • Business Wire2 months ago

    NovaBay Pharmaceuticals to Hold First Quarter 2019 Conference Call on May 9, 2019

    Management to discuss new partner pharmacy program and expanded access to in-office direct channel

  • Business Wire2 months ago

    NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will hold a virtual Annual Meeting of Stockholders on Thursday, May 30, 2019 at 5:00 p.m. Pacific time. Registered holders and beneficial stockholders, who register for the meeting in advance, will be able to participate in the meeting, vote and submit questions during the meeting via a live webcast by visiting www.meetingcenter.io/263757134. The Company also notes that on April 12, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Section 1003(a)(iii) of the NYSE American Company Guide requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years.

  • Business Wire2 months ago

    NovaBay Pharmaceuticals Announces New Partner Pharmacy Program

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company, announces a new pharmacy partnering program in a continued effort to ensure all patients in the U.S. have reliable and affordable access to prescription Avenova®. The company’s pharmacy partners serve patients across the U.S., and together ensure patients in all 50 states have convenient access to Avenova. “Our commitment to a quality patient experience, along with our expanding national presence ensures every patient who wants Avenova can obtain it at the best price,” said Dan Richards, CEO of Meds In Motion Pharmacy, one of Avenova’s channel partners.

  • Business Wire3 months ago

    NovaBay Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • ACCESSWIRE3 months ago

    NovaBay Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 28, 2019 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 28, ...

  • Business Wire3 months ago

    NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy

    Makes board and executive changes and reduces U.S. sales organization to focus only on high-performing, high potential sales territories and specialty pharmacy channel expansion

  • Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for
    Zacks3 months ago

    Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for

    NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire5 months ago

    NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales and Introduces 2019 Net Sales Guidance

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces 2018 net sales are expected to be $12.6 million to $12.7 million. “During 2018 we launched a number of refinements to our Avenova commercial strategy as we gained experience from our initial approach,” said Jack McGovern, NovaBay Interim CEO and CFO. “Key drivers of our expected growth include engaging specialty pharmacy providers as channel partners, which provides the dual benefit of significantly improving the overall patient experience and supporting higher per-unit revenue,” he added.

  • Business Wire7 months ago

    NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • Business Wire7 months ago

    NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report third quarter 2018 financial results after market close on Wednesday, November 14.

  • Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know
    Zacks7 months ago

    Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know

    NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire9 months ago

    NovaBay Pharmaceuticals Names Jack McGovern Interim CEO

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that Jack McGovern has been named Interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the Company’s previous Chief Executive Officer, remains NovaBay’s Chairman and will focus on strategic growth opportunities that complement the Company’s continued organic growth.

  • Business Wire10 months ago

    NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C.

  • Business Wire10 months ago

    NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • Business Wire11 months ago

    NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report second quarter 2018 financial results after market close on Tuesday, August 7.

  • Business Wire11 months ago

    NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring of 7 sales representatives. The Company now has a commercial salesforce of 45 representatives as the Company pursues profitable growth. “We are very encouraged by the high quality of our new hires, all of whom have significant experience in promoting prescription ophthalmic products,” said Mark M. Sieczkarek, NovaBay’s Chairman, President and CEO.